Loading...
Loading...
AKRO| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.3M |
| Operating Expense | 61.9M |
| Operating I/L | -61.9M |
| Other Income/Expense | 6.7M |
| Interest Income | 7.6M |
| Pretax | -55.2M |
| Income Tax Expense | -12.5M |
| Net Income/Loss | -55.2M |
Akero Therapeutics, Inc. is a cardio-metabolic nonalcoholic steatohepatitis (NASH) company specializing in the development of medicines aimed at restoring metabolic balance and enhancing overall health. The company's primary focus is on efruxifermin (EFX), an analog of fibroblast growth factor 21, designed to protect against cellular stress and regulate metabolism of lipids, carbohydrates, and proteins in the body. Akero Therapeutics, Inc. generates revenue through the development and potential commercialization of EFX, with a current emphasis on the Phase 2a clinical trial, the BALANCED study, to assess EFX's efficacy in treating biopsy-confirmed NASH patients.
